A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Complete Title: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Trial Phase: I/II

Investigator: Mazyar Shadman

The purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back or did not respond to previous treatment.

Keywords:

Hematologic Malignancies
Leukemia
Lymphoma
Lymphoproliferative Disorders
Lymphoma, Non-Hodgkin (NHL)
Leukemia, Lymphoid
Immunoproliferative Disorders
Waldenstrom Macroglobulinemia
Lymphoma, Mantle-Cell
Cardiovascular Diseases
Lymphoma, B-Cell
Lymphoma, Follicular
Leukemia, B-Cell
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms, Plasma Cell
Paraproteinemias
Lymphoma, Large B-Cell, Diffuse
Immune System Diseases
Hemorrhagic Disorders
Hematologic Diseases
Lymphoma, B-Cell, Marginal Zone

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.